|Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark|
T Jess, L Riis, I Vind, KV Winther, S Borg, V Binder, E Langholz, ...
Inflammatory bowel diseases 13 (4), 481-489, 2006
|The costs of exacerbations in chronic obstructive pulmonary disease (COPD)|
F Andersson, S Borg, SA Jansson, AC Jonsson, ÅSA ERICSSON, C Prütz, ...
Respiratory medicine 96 (9), 700-708, 2002
|Costs of COPD in Sweden according to disease severity|
SA Jansson, F Andersson, S Borg, Å Ericsson, E Jönsson, B Lundbäck
Chest 122 (6), 1994-2002, 2002
|A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease|
S Borg, Å Ericsson, J Wedzicha, A Gulsvik, B Lundbäck, GC Donaldson, ...
Value in Health 7 (2), 153-167, 2004
|Obesity, survival, and hospital costs—findings from a screening project in Sweden|
S Borg, U Persson, K Ödegaard, G Berglund, JÅ Nilsson, PM Nilsson
Value in Health 8 (5), 562-571, 2005
|Costs and quality of life in multiple sclerosis patients with spasticity|
J Svensson, S Borg, P Nilsson
Acta neurologica Scandinavica 129 (1), 13-20, 2014
|The impact of exacerbations on the asthmatic patient's preference scores|
F Andersson, S Borg, E Ståhl
Journal of Asthma 40 (6), 615-623, 2003
|Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios|
M Hoogendoorn, TL Feenstra, Y Asukai, S Borg, RN Hansen, SA Jansson, ...
Value in Health 17 (5), 525-536, 2014
|Drug and treatment costs in Parkinson’s disease patients in Sweden|
J Lökk, S Borg, J Svensson, U Persson, G Ljunggren
Acta Neurologica Scandinavica 125 (2), 142-147, 2012
|The Swedish cost burden of overweight and obesity–evaluated with the PAR approach and a statistical modelling approach|
K Odegaard, S Borg, U Persson, M Svensson
International Journal of Pediatric Obesity 3 (sup1), 51-57, 2008
|Budesonide/formoterol in a single inhaler (Symbicort) reduces healthcare costs compared with separate inhalers in the treatment of asthma over 12 months.|
L Rosenhall, S Borg, F Andersson, K Ericsson
International journal of clinical practice 57 (8), 662-667, 2003
|Factors affecting chronic obstructive pulmonary disease (COPD)-related costs: a multivariate analysis of a Swedish COPD cohort|
UG Gerdtham, LF Andersson, Å Ericsson, S Borg, SA Jansson, ...
The European Journal of Health Economics 10 (2), 217-226, 2009
|Cost differences for COPD with and without physician-diagnosis|
SA Jansson, A Lindberg, Å Ericsson, S Borg, E Rönmark, F Andersson, ...
COPD: Journal of Chronic Obstructive Pulmonary Disease 2 (4), 427-434, 2005
|Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden|
T Hofmarcher, S Borg
Journal of medical economics 18 (7), 492-501, 2015
|The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model|
S Borg, AH Glenngård, A Österborg, U Persson
Acta Oncologica 47 (6), 1009-1017, 2008
|Cost-effectiveness analysis of budesonide/formoterol compared with fluticasone in moderate-persistent asthma|
K Ericsson, TA Bantje, RM Huber, S Borg, ED Bateman
Respiratory medicine 100 (4), 586-594, 2006
|Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: Comparative analysis of drug utilization, costs, and …|
U Persson, S Borg, S Jansson, T Ekman, L Franksson, S Friesland, ...
Advances in therapy 22 (3), 208-224, 2005
|Comparative cost-effectiveness of anticoagulation with bivalirudin or heparin with and without a glycoprotein IIb/IIIa-receptor inhibitor in patients undergoing percutaneous …|
S Borg, U Persson, K Allikmets, K Ericsson
Clinical therapeutics 28 (11), 1947-1959, 2006
|Patient-reported outcome measures and risk factors in a quality registry: a basis for more patient-centered diabetes care in Sweden|
S Borg, B Palaszewski, UG Gerdtham, Ö Fredrik, P Roos, ...
International journal of environmental research and public health 11 (12 …, 2014
|Patient heterogeneity in health economic decision models for chronic obstructive pulmonary disease: are current models suitable to evaluate personalized medicine?|
M Hoogendoorn, TL Feenstra, Y Asukai, AH Briggs, S Borg, ...
Value in Health 19 (6), 800-810, 2016